Cited 12 time in
Causative Agents of Drug-Induced Pancreatitis: A Nationwide Assessment
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Chung, Eun Kyoung | - |
| dc.contributor.author | Lee, Ji Hyun | - |
| dc.contributor.author | Jang, Dong Kee | - |
| dc.contributor.author | Lee, Sang Hyub | - |
| dc.contributor.author | Lee, Jin Ho | - |
| dc.contributor.author | Park, Byung-Joo | - |
| dc.contributor.author | Kwon, Kyenghee | - |
| dc.contributor.author | Lee, Jun Kyu | - |
| dc.date.accessioned | 2023-04-28T06:42:10Z | - |
| dc.date.available | 2023-04-28T06:42:10Z | - |
| dc.date.issued | 2018-11 | - |
| dc.identifier.issn | 0885-3177 | - |
| dc.identifier.issn | 1536-4828 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/8944 | - |
| dc.description.abstract | Objectives The aim of this study was to analyze causes of drug-induced acute pancreatitis (DIAP) in Korea and factors associated with serious DIAP. Methods Case records of DIAP voluntarily reported to the Korea Adverse Event Reporting System from 2004 to 2013 were reviewed. When a patient took 2 or more drugs, each drug was identified as a potential cause. The seriousness of each case was determined based on the International Conference on Harmonization E2D Guideline. Logistic regression was performed to identify factors associated with the seriousness of DIAP. Results During the study period, 210 (0.05%) of 442,523 adverse event reports were (0.05%) DIAP. The most common causative medication of the DIAP cases with certain, probable/likely, and possible causality (n = 74) was l-asparaginase (n = 18), followed by azathioprine (n = 6), methylprednisolone (n = 6), and fenofibrate (n = 5). Serious events occurred in 43 cases (58%) with certain, probable/likely, and possible causality. They were significantly associated with the year of report (odds ratio, 0.572; P = 0.025) and the number of concurrently used medications (odds ratio, 2.659; P = 0.006). Conclusions l-Asparaginase is the most common cause of DIAP in Korea. Serious DIAP is more likely to occur in patients taking multiple medications. | - |
| dc.format.extent | 9 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
| dc.title | Causative Agents of Drug-Induced Pancreatitis: A Nationwide Assessment | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1097/MPA.0000000000001152 | - |
| dc.identifier.scopusid | 2-s2.0-85055079654 | - |
| dc.identifier.wosid | 000449304600026 | - |
| dc.identifier.bibliographicCitation | PANCREAS, v.47, no.10, pp 1328 - 1336 | - |
| dc.citation.title | PANCREAS | - |
| dc.citation.volume | 47 | - |
| dc.citation.number | 10 | - |
| dc.citation.startPage | 1328 | - |
| dc.citation.endPage | 1336 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | sci | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
| dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
| dc.subject.keywordPlus | ASPARAGINASE-ASSOCIATED PANCREATITIS | - |
| dc.subject.keywordPlus | MANAGEMENT | - |
| dc.subject.keywordPlus | EPIDEMIOLOGY | - |
| dc.subject.keywordPlus | GUIDELINES | - |
| dc.subject.keywordPlus | THERAPY | - |
| dc.subject.keywordAuthor | adverse drug events | - |
| dc.subject.keywordAuthor | drug-induced acute pancreatitis | - |
| dc.subject.keywordAuthor | pharmacovigilance | - |
| dc.subject.keywordAuthor | polypharmacy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
